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The incidence of microemboli to the brain is less
with endarterectomy than with percutaneous
revascularization with distal filters or flow reversal
Naren Gupta, MD, PhD,a Matthew A. Corriere, MD, MS,a,c Thomas F. Dodson, MD,a
Elliot L. Chaikof, MD, PhD,a Robert J. Beaulieu, BS,b James G. Reeves, MD,a Atef A. Salam, MD,a and
Karthikeshwar Kasirajan, MD,a Atlanta, Ga
Background: Current data suggest microembolization to the brain may result in long-term cognitive dysfunction despite
the absence of immediate clinically obvious cerebrovascular events. We reviewed a series of patients treated electively with
carotid endarterectomy (CEA), carotid artery stenting (CAS) with distal filters, and carotid stenting with flow reversal
(FRS) monitored continuously with transcranial Doppler scan (TCD) during the procedure to detect microembolization
rates.
Methods: TCD insonation of the M1 segment of the middle cerebral artery was conducted during 42 procedures (15 CEA,
20 CAS, and 7 FRS) in 41 patients seen at an academic center. One patient had staged bilateral CEA. Ipsilateral
microembolic signals (MESs) were divided into three phases: preprotection phase (until internal carotid artery [ICA]
cross-shunted or clamped if no shunt was used, filter deployed, or flow reversal established), protection phase (until
clamp/shunt was removed, filter removed, or antegrade flow re-established), and postprotection phase (after clamp/
shunt was removed, filter removed, or antegrade flow re-established). Descriptive statistics are reported as mean SE for
continuous variables and N (%) for categorical variables. Differences in ipsilateral emboli counts based on cerebral
protection strategy were assessed using nonparametric methods.
Results: TCD insonation and procedural success were obtained in 33 procedures (79%; 14 CEA, 14 CAS, and 5 FRS).
Highest ipsilateral MESs were observed for CAS (319.3  110.3), followed by FRS (184.2  110.5), and CEA (15.3 
22.0). Pairwise comparisons revealed significantly higher ipsilateral MESs with both FRS and CAS when compared to
CEA (P  .007 for FRS and P < .001 for CAS vs CEA, respectively), whereas the difference in MESs between FRS and
CAS was not significant (P  .053). Periods of maximum embolization were postprotection phase for CEA, protection
phase for CAS, and preprotection phase for FRS. Preprotection MESs were frequently observed during both CAS and
FRS (20.4% and 63.3% of total MESs across all phases, respectively), and the primary difference between these two
methods seemed to be related to lower MESs during the protection phase with FRS.
Conclusion: CEA is associated with lower rates of microembolization compared with carotid stenting. Flow reversal may
represent a procedural modification with potential to reduce microembolization during carotid stenting; further
investigation is warranted to determine the relationship between cerebral protection strategies and outcomes associated
with carotid stenting. (J Vasc Surg 2011;53:316-22.)
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pStroke affects nearly 800,000United States citizens annu-
ally and is the third most common cause of death in the
United States.1 Almost 20% of strokes are due to atheroscle-
rotic disease of the extracranial carotid arteries.2 The surgical
removal of the source of emboli or flow limitation by carotid
endarterectomy (CEA) has been shown to decrease the risk of
stroke compared to medical therapy alone.3-6 Carotid angio-
plasty stenting (CAS) gained acceptance as a minimally inva-
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316ive alternative to CEA with the Stenting with Angioplasty
nd Protection in Patients at High Risk for Endarterectomy
SAPPHIRE) trial, which concluded that CAS was noninfe-
ior to CEA in a high-risk group of patients, despite higher
troke rates in the CAS arm.7 Four subsequent prospective
andomized trials have all demonstrated higher stroke rates
ith CAS compared to CEA.8-11 The recent Carotid Revas-
ularization Endarterectomy vs Stenting Trial deployed a late-
eneration stent with 96% distal filter deployment and vigor-
us credentialing of interventionalists, yet reported that the
mpact on quality of life of the increased number of strokes
fter CAS (4.1% vs 2.3%; P .01) was more than that due to
ncreased cardiac events after CEA (1.1% vs 2.3%;
 .03).11
Intracerebral microembolization is implicated in the
ncreased cerebral events after percutaneous revasculariza-
ion.12,13 Distal embolic protection filtering devices were
ntroduced to reduce microembolization but do not com-
letely eliminate this phenomenon due in part to the lack of
rotection during instrumentation of the aortic arch and
nitial passage across the carotid lesion and a failure to
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Volume 53, Number 2 Gupta et al 317capture all emboli after deployment.14,15 Flow reversal
(FRS) is an embolic protectionmethod that addresses some
of the shortcomings of distal filters by reversing the direc-
tion of blood flow in the distal internal carotid artery (ICA).
A commercial FRS system received Food and Drug Admin-
istration approval to be marketed in the United States in
February 2009.16,17
Microemboli are detected as high-intensity unidirec-
tional transient signals on transcranial Doppler (TCD) scan
imaging during the procedure.18 These microembolization
signals (MESs) correspond to gaseous or particulate em-
bolic material: both are related to adverse clinical out-
comes.19-21 There is evidence that MESs may also contrib-
ute to vascular dementia and Alzheimer’s disease.22
Monitoring of MESs by TCD has been used as a quality
control method during both open and percutaneous carotid
revascularization.23,24 The objective of this study was to de-
termine MES rates during elective CEA, carotid angioplasty,
and stenting with distal embolic protection device or carotid
angioplasty and stenting with flow reversal (FRS).
METHODS
Institutional review board approval was obtained to
retrospectively analyze a prospectively collected database of
patients who had undergone elective carotid revasculariza-
tion under TCD monitoring. The TCD endpoint was the
total number of ipsilateral MESs generated during the
procedure. These signals were divided into three groups:
preprotection phase (until the ICA is cross-shunted or
clamped if no shunt was used, filter deployed, or flow
Table I. Baseline patient characteristics
CEA (N  14) CA
Mean age 72  8 67.
Male 10 (71.4) 1
Symptomatic 7 (50)
DM 9 (64.3)
CHF (NYHA III or IV) 2 (14.3)
CAD 2 (14.3)
COPD (FEV11) 0 (0) 4
Previous MI 6 (42.9) 5
Tobacco 1 y 4 (28.6) 6
CRI (Cr 1.4) 3 (21.4) 3
HTN 14 (100) 14
PVD 3 (21.4) 8
Hyperlipidemia 10 (71.4) 12
Right-sided lesion 5 (35.7) 3
Irradiated neck 0 (0) 4
Restenosis 1 (7.1) 1
C/L disease 80% to 99% 1 (7.1) 2
C/L occlusion 1 (7.1) 1
Bovine arch N/A 2
Type II or III arch N/A 9
CAD, Coronary artery disease; CAS, carotid artery stenting; CEA, carotid en
obstructive pulmonary disease; Cr, creatinine; CRI, chronic renal insufficien
reversal stenting; HTN, hypertension; N/A, not applicable; NYHA, New
disease.
Data displayed as mean  SD for continuous variables and number (percenreversal established), protection phase (until clamp/shunt ras removed, filter removed, or antegrade flow re-estab-
ished), and postprotection phase (after clamp/shunt was
emoved, filter removed, or antegrade flow re-established).
Patients. Between December 2008 and December
009, a total of 163 carotid revascularization procedures
83 CEA, 59 CAS, and 21 FRS) were performed at this
nstitution. Treatment for asymptomatic disease was of-
ered for stenosis greater than 80% by North American
ymptomatic Carotid Endarterectomy Trial criterion, and
or symptomatic patients, the cutoff was 70%.6 Stenosis
as determined by duplex ultrasound scan imaging. Patient
election for TCDmonitoring was based on the availability
f a technician. Forty-two (25.2% of the total caseload)
arotid revascularization procedures (15 CEA, 20 CAS,
nd 7 FRS) in 41 individuals (1 patient had staged bilateral
EA) had TCD monitoring and their data were prospec-
ively entered into a database. Procedures were aborted in
hree instances (7.1%; 2 CAS, 1 FRS): 1 patient for CAS
ad a calcified type III arch leading to an inability to
annulate the left CCAwith a 6F sheath, in another patient,
he lesion seemed to be a chronic dissection with distal
neurysmal changes that extended intracranially. An FRS
ase was aborted due to the inability to place the ECA
alloon and the presence of large ECA collaterals that,
ombined, prevented reversal of flow. Insonation failure
ue to poor acoustic windows occurred in another 6 pro-
edures (14.3%), yielding 33 revascularizations that were
oth technical and insonation successes (14 CEA, 14 CAS,
nd 5 FRS).
The baseline patient characteristics based on carotid
 14) FRS (N  5) Total (N  33)
.2-73.2) 63.1 (58.8-67.1) 68.0 (63.3-77.6)
.6) 5 (100) 26 (78.8)
.7) 3 (60) 15 (45.5)
) 3 (60) 19 (57.6)
) 3 (60) 6 (18.2)
.7) 3 (60) 10 (30.3)
.5) 2 (40) 6 (18.2)
.7) 3 (60) 14 (42.4)
.9) 0 (0) 10 (30.3)
.4) 2 (40) 8 (24.4)
0) 4 (80) 32 (96.8)
.1) 2 (40) 13 (39.4)
.7) 4 (80) 26 (78.8)
.4) 5 (100) 13 (39.3)
.5) 0 (0) 4 (12.1)
) 0 (0) 2 (6.1)
.3) 0 (0) 3 (9.1)
) 2 (40) 4 (12.1)
.3) 0 (0) 2 (10.5)
.3) 5 (100) 14 (73.7)
rectomy; CHF, congestive heart failure; C/L, contralateral; COPD, chronic
, diabetes mellitus; FEV1, forced expiratory volume in 1 second; FRS, flow
Hospital Association; MI, myocardial infarction; PVD, peripheral vascular
categorical variables.S (N
5 (64
1 (78
5 (35
7 (50
1 (7.1
5 (35
(28
(35
(42
(21
(10
(57
(85
(21
(28
(7.1
(14
(7.1
(14
(64
darte
cy;DM
Yorkevascularization and embolic protection are summarized
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February 2011318 Gupta et alin Table I. Mean age was 69.6  8.6 years, and 7 (21.2%)
were women. Coronary artery disease, hypertension, diabe-
tes, and hyperlipidemia were prevalent among all treatment
groups, and all treatment groups included both symptom-
atic and asymptomatic patients.
CEA. One procedure was done with the patient under
local anesthesia, the rest were done with the patients under
general anesthesia. Ten patients were given aspirin before
the procedure, 1 patient was on aspirin and clopidogrel,
and 3 patients took neither drug despite recommendations.
Bovine pericardial patch closures were used for 10 patients
(71.4%), Dacron for 2 patients (14.3%), saphenous vein
patch for 1 patient (7.1%), and 1 was closed primarily
(7.1%). Shunts were used in 4 of 14 CEAs (28.6%). One
surgeon routinely shunted, the others selectively shunted
based on cerebral oximeter drop of 20% or neurologic
changes in awake patients. Heparin was reversed with pro-
tamine. Drains were placed in all. Patients were kept over-
night and discharged on 81 mg aspirin. Follow-up was at
30 days with a clinic visit and a neurologic examination.
Percutaneous revascularization with distal embolic
protection carotid artery stenting. Patients who met the
SAPPHIRE high-risk criterion7 were offered CAS by expe-
rienced endovascular specialists, each with greater than 50
procedures as the primary operator. Patients were on 81mg
aspirin preoperatively with the exception of 2 individuals: 1
with chronic atrial fibrillation who had been on aspirin and
Coumadin preoperatively, and another on clopidogrel
alone due to an aspirin allergy. All the others were either on
clopidogrel 75mg daily in addition to the aspirin before the
procedure, or were loaded with 300mg immediately before
the procedure. A preprocedure neurologic examination was
performed. Access was through the groin with the patient
under local anesthesia with no systemic sedation. Patients
were heparinized to an activated clotting time 300, an
arch angiogram was performed, and the target carotid was
selectively cannulated. The contralateral carotid was not
selectively cannulated. Lesions were selectively predilated
with 3- or 4-mm balloons after filter deployment. Filters
used included Angioguard (Cordis Corporation, Bridge-
water, NJ; N  9), Rx Accunet (Abbott Vascular, Santa
Clara, Calif; N  3) and SpiderFx (EV3 Endovascular Inc,
Plymouth, Minn; N  2). Seven- or 8-mm self-expanding
stents were deployed and postdilated to 5 or 6 mm. Stents
used included Precise (Cordis Corporation; N  10), Pro-
tégé RX (EV3 Endovascular Inc; N  2), and Rx Acculink
(Abbott Vascular; N  2). Atropine was administered
selectively. Residual stenosis 20% was accepted as an
adequate result. Heparin was not reversed and vascular
closure devices were used to close the access site. Patients
were admitted to the hospital and discharged the following
day, or if they had labile pressures postprocedure, when
their blood pressure normalized. Postoperatively, all pa-
tients received 30 days of dual antiplatelet therapy, again
with the exception of the 2 patients mentioned before, 1 of
whom received lifelong Clopidogrel and the other aspirin
and Coumadin. Follow-up was in a clinic in 30 days with a puplex ultrasound scan of the carotids and a neurologic
xamination.
Percutaneous revascularization with flow reversal.
atients who met the SAPPHIRE high-risk criteria7 and
ad anatomic contraindications to distal filter deployment
loops or acute bends in the filter landing zone), were
ffered percutaneous revascularization with flow reversal
sing the Neuro Protection System (NPS; W. L. Gore and
ssociates, Flagstaff, Ariz). One vascular surgeon who had
ompleted more than 50 cases with this device, performed
ll these procedures. All patients were on 81 mg aspirin and
5 mg clopidogrel before the procedure. Briefly, the pa-
ient’s common femoral artery was accessed with a 9F
heath, and a 6F venous sheath was placed in the contralat-
ral groin with the patient under local anesthesia with no
edation. Patients were systemically heparinized to an acti-
ated clotting time 250. An arch angiogram was ob-
ained. The contralateral carotid was not selectively cannu-
ated. The flow reversal device was positioned in the
ommon carotid artery and the target lesion imaged. The
ommon and external carotid balloons were inflated and
iagnostic angiograms were obtained to confirm flow re-
ersal. Lesions were selectively predilated with 3- or 4-mm
alloons after confirmation of flow reversal. Atropine was
iven selectively. Self-expanding stents were deployed and
ostdilated as previously described. Stents used in combi-
ation with flow reversal included the Precise (N  4) and
x Acculink (N  1). After angioplasty and stenting the
esion, the balloons were deflated while aspirating the col-
mn of blood. Vascular closure devices were used on the
rterial access site and manual pressure applied to the
enipuncture site. Heparin was not reversed and the pa-
ients received dual antiplatelet therapy for 30 days post-
rocedure.
Transcranial Doppler scan monitoring. Successful
ontinuous transtemporal insonation of theM1 segment of
he ipsilateral middle cerebral artery during the revascular-
zation procedure was achieved in 33 of 42 cases (78.6%)
sing the ST3/PMD 150 (Spencer Technologies, Seattle,
ash), a portable digital transcranial Doppler scan pulsed-
ave system. A Marc Series Headframe (Spencer Technol-
gies, Seattle, Wash) was used to secure the transducer
nterosuperior to the ipsilateral ear allowing insonation
hrough the posterior temporal bone window. This system
as a Power M-Mode with 33 gates of continuous Doppler
can information across a 66-mm depth range and a spec-
rogram screen showing a Doppler scan spectral waveform,
ndicating the velocity profile of blood at a depth that can
e selected in the Power M-Mode screen. It has automatic
mbolus detection software that detects, time dates, and
ounts all MESs with the ability to separate these signals
rom artifact or noise. The automatic detection system is
ffective across a wide insonation gate that was set between
5 and 65 mm. The M1 segment of the middle cerebral
rtery was positively identified at around 50 mm depth as a
ontinuation of the supraclinoid ICA, running laterally up
o approximately 30 mm with flow directed toward the
robe and a signal responding to ipsilateral vibration or
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The M-Mode and spectral waveform tracings, the auto-
mated count, and the accompanying Doppler scan audible
output were monitored and recorded continuously. An
ongoing narration of the entire procedure was recorded
and spliced into the Doppler scan tracings. All these data
were stored in an internal hard drive. Simultaneously, a
chronologic documentation of the procedure was main-
tained. This allowed for a precise timeline of events such as
angiograms, lesion crossing, and cross-clamping to be cor-
related accurately with the events on TCD. The TCD
tracings, audible output, narration, and case documenta-
tion were reviewed independently by two investigators
postprocedure, and the automated count of MESs audited
based on Consensus Committee guidelines, which define
MESs as transient (300 msec), 3dB above background
flow, unilateral in Doppler scan spectrum, and accompa-
nied by an audible chirp.25 The automatically generated
software count was reviewed by two observers as a means of
quality control. Due to the high level of agreement, and to
avoid interobserver variance, the automated software count
was used in the statistical analysis.
Statistical analysis. Summary statistics are reported as
mean SD for continuous variables and number (percent)
for categorical variables. Differences in MESs between pa-
tient groups based on revascularization/protection strat-
egy were assessed using nonparametric methods (Kruskal-
Wallis and Wilcoxon rank-sum tests), and exact methods
were used for all comparisons in which N 10 for any
group. The main hypothesis was assessed at   0.05, and
the Bonferroni method was used to adjust for multiple tests
(N  3) with a significance criterion of P  .017 for each
comparison. All statistical calculations were performed us-
ing SAS version 9.2 (SAS Institute, Cary, NC).
RESULTS
Clinical outcomes. Mean procedure duration was
54.5  4.2 minutes for CEA, 46.3  17.8 minutes for
CAS, and 66.0  2.2 minutes for FRS. There were no
deaths, clinically evident cerebral events, cranial nerve inju-
ries, or wound complications within 30 days postproce-
dure. All patients underwent postdischarge carotid duplex
ultrasound scan without evidence of restenosis and/
or stent thrombosis at the time of their first outpatient
follow-up visit. Neurologic examination at the 30-day visit
did not reveal any deficits. One patient with chronic atrial
fibrillation in the CAS group suffered a gastrointestinal
bleed 2 weeks after her carotid revascularization; she had
been discharged on her first day after CAS on her preoper-
ative home medications, including aspirin and warfarin.
This same patient had a postoperative myocardial infarction
after discharge.
Transcranial Doppler scan outcomes. Highest ipsi-
lateral MESs were observed for CAS (319.3  110.3),
followed by FRS (184.2 110.5), and CEA (15.3 22.0;
Fig). Pairwise comparisons based on procedural manage-
ment revealed significantly higher ipsilateral MESs for both
FRS andCASwhen compared with CEA (P .007 for FRS lnd P  .001 for CAS vs CEA, respectively). Mean ipsilat-
ral MESs with CAS were 319.3 110.3 vs 184.2 110.5
ith FRS, but this difference was not significant (P .053).
nalysis of ipsilateral MESs based on protection phase
evealed that the periods of maximum embolization dif-
ered between procedures (Table II). Maximum MESs
ere observed during the postprotection phase for CEA,
uring the protection phase for CAS, and during the pre-
rotection phase for FRS. Preprotection MESs were fre-
uently observed during both CAS and FRS (20.4% and
3.3% of total MESs across all phases, respectively), and the
rimary difference between these two methods seemed to
e related to lower MESs during the protection phase with
RS. Adjusted analyses of MESs based on patient demo-
raphics or anatomic factors were not performed due to the
mall sample size.
ISCUSSION
This study of a series of carotid revascularizations dem-
nstrated that microembolization (MES) rates by TCD
onitoring were the least for CEA compared to percuta-
eous revascularization with distal embolic protection de-
ices (CAS) or FRS. Lower raw MES rates were observed
ith FRS vs CAS with distal protection, particularly during
he protection phase of the procedure, but this difference
as not statistically significant. These data suggest that flow
eversal may offer advantages over distal filters for reducing
rocedure-related microembolization, but further data col-
ig. Ipsilateral microembolic signals (MESs) based on procedure.
pper and lower sides of the “boxes” represent the 75th and 25th
ercentiles for each group, respectively; horizontal lines represent
he median for each group; the ends of the “whiskers” extend to
he 90th and 10th percentiles; outliers are indicated by the “plus”
ymbols. CAS, Carotid artery stenting; CEA, carotid endarterec-
omy; FRS, flow reversal stenting.ection and analyses are needed to verify this hypothesis.
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February 2011320 Gupta et alDuring stent deployment and angioplasty, particulate em-
boli predominate and cause greater damage than the show-
ers of emboli that occur with flushing or exchanging cath-
eters, which have a more gaseous composition.21 During
FRS, pressurized forward flow in the protection phase can
momentarily overcome the reversal of flow, leading to the
occurrence of MESs.26
Stroke is the third most common cause of death in the
United States and a leading cause of serious disability, with
an estimated direct and indirect cost of $73.7 billion in
2010.1 CEA is one of the most extensively evaluated inter-
ventions for reducing the risk of stroke after extracranial
carotid atherosclerotic disease. Despite the early predic-
tions that carotid angioplasty and stenting with distal pro-
tection (CAS) would surpass it in popularity, CEA remains
the most common intervention for atherosclerotic disease
of the extracranial carotid arteries for stroke prevention.1
One of the contributing factors to this resistance to
widespread adoption of CAS instead of CEA is ongoing
concern regarding the higher rate of embolic debris from a
disrupted plaque creating clinically apparent and subclinical
neuronal damage. The risk of developing new cortical
lesions on diffusion-weighted magnetic resonance imaging
(DW-MRI) after CAS is several-fold greater than after
CEA.27,28 These lesions may be subclinical, but they create
persistent and detectable abnormalities on follow-up
MRI.29 Although the clinical effect of these lesions over
time is not known for certain, there is an increasing burden
of evidence that they are not benign. Subclinical infarcts
seen on MRI were noted to be a risk factor for mild
cognitive impairment by the Cardiovascular Health Study
Cognition study.30 In a population-based cohort study of
more than 1000 elderly individuals, silent infarcts on MRI
were found to contribute to cognitive decline and an in-
creased risk of dementia and a threefold increased risk of
subsequent stroke.31,32
The likely reason for these new lesions is due to partic-
ulate and gaseous embolism during the various steps of
carotid angioplasty.33,34 Bendszus et al35 was the first to
report the occurrence of silent embolism identified by new
DW-MRI lesions after diagnostic or interventional arch
angiography and subsequently demonstrated a decrease in
the incidence of MESs as detected by TCD and silent
infarcts detected by DW-MRI with the use of air filters.36
Puggsley et al37 demonstrated that MES detected by TCD
occurred during cardiopulmonary bypass, and patients who
Table II. Mean ipsilateral MESs based on protection phas
Preprotection Pr
CEA (N  14) 4.7  9.9 0.4
CAS (N  14) 121.8  60.5 187.6
FRS (N  5) 115.2  85.8 33.
Total (N  33) 71.1  76.2 84.
CAS, Carotid artery stenting; CEA, carotid endarterectomy; FRS, flow reve
aP  .001 for CEA vs CAS, P  .001 for CEA vs FRS, P  .054 for CAS vhad greater than 1000 microembolisms were more likely to cave associated with cognitive decline after 7 days. They
urther showed that the MES rate and the risk of cognitive
ecline decreased with the use of 40-micron filters in the
rterial line.37 In response to concerns about distal embo-
ization of particulate matter from disrupted plaques,
heron et al38 advocated the use of distal filters for embolic
rotection during CAS in 1996, and their use has become
idespread despite the fact that they are not completely
ffective in preventing distal embolization: embolization of
articles greater than 500 microns have been demonstrated
istal to a variety of commonly used filters.21,39
The correlation of intraoperative microembolization
etected by TCD monitoring during CEA and subsequent
troke was demonstrated as early as 1994,40 leading to
ork that proposed a utility for TCD monitoring as a
uality control method during open carotid revasculariza-
ion.41 Similarly, Ackerstaff et al18,20 demonstrated an as-
ociation between MES detected by TCD during CAS and
dverse cerebral outcomes. More recently, an association
etween MES (detected by TCD during both CEA and
AS with distal embolic protection), new DW-MRI le-
ions, and ipsilateral ischemic stroke was described in a
rospective Norwegian study.21
The cardinal principal of CEA is distal control before
anipulation of the lesion by clamping or shunting before
ndarterectomy and patch angioplasty. This ensures that
here is minimal opportunity for debris from a manipulated
laque to embolize into the distal circulation: the occur-
ence of distal embolization has been shown to be the
ighest during dissection and shunting.42 In contrast, dur-
ng CAS with distal filters, initial manipulation of the arch
nd crossing of the lesion generate emboli without any
rotection, once the filter is deployed the protection of-
ered is incomplete, as through-filter and perifilter escape of
ebris is well-documented, and the occurrence of strokes
espite the deployment of a distal embolic protection de-
ice confirms this.43 The result is an increased amount of
mbolic debris entering the distal cerebral circulation in
AS compared to CEA.21 Modifications to CAS exist that
eek to emulate the surgical principal of establishing distal
erebral protection before manipulating the lesion by flow
rrest or flow reversal. Flow arrest is an embolic protection
ethod that involves occlusion of the CCA and ECA with
alloons before angioplasty and aspiration of the standing
olumn of blood containing embolic debris from the dis-
upted plaque after angioplasty. A proximal arrest system
procedure
on Postprotection Totala
.8 10.2  12.2 15.3  22.0
0.7 21.8  16.0 319.3  110.3
9.0 36.0  48.0 184.2  110.5
04.1 19.0  23.1 169.8  164.1
enting; MESs, microembolic signals.
.e and
otecti
 0
 8
2  1
8  1
rsal stalled the Mo.Ma device (Medtronic Invatec, Frauenfeld,
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Volume 53, Number 2 Gupta et al 321Switzerland) has received Food & Drug Administration
approval.44 Although our institution does not have experi-
ence with this device, others have shown a decrease in MES
rates with proximal flow arrest compared to CAS embolic
protection device.45 Flow reversal takes this concept a step
further by occluding both the CCA and the ECA and then
establishing a closed circuit that drains the stagnant column
of blood in the ICA through a filter and into the patient’s
own venous system, typically through the femoral vein. An
added benefit with both flow arrest and flow reversal is the
avoidance of iatrogenic complications associated with distal
filter placement, namely vasospasm, carotid dissection, and
guidewire entrapment. Patients with bends or loops in the
filter’s landing zone are also good candidates for flow
reversal. Our data suggest that FRS may be associated with
fewer MESs during the protection phase of stenting, but it
is important to note that this difference was nonsignificant.
Use of FRS was associated with significantly more micro-
emboli than CEA, demonstrating that other procedural
steps (such as arch manipulations, catheter exchanges, and
perhaps temporary loss of flow reversal with untempered
positive pressure flushes) still produce MESs with this tech-
nique.
In our study, despite the majority of our patients get-
ting preoperative computed tomographic angiography or
magnetic resonance angiography of the arch, we obtained
arch angiograms in all patients before selective cannulation
of the target carotid. It has been shown by some investiga-
tors that omitting the arch angiogram, early heparinization,
and preferential use of closed-cell stents reduced the rate of
new DW-MRI lesions.24 We believe that in our hands, an
arch angiogram minimizes catheter manipulation in the
arch during selective carotid cannulation and limits the
particulate embolic debris.
The principal limitation of this study is the small sample
size, particularly in the FRS group. Power limitations re-
lated to the limited number of patients impaired our ability
to detect treatment effects and adjust for confounding
factors related to patient selection based on high-risk crite-
ria. Future extension of these exploratory analyses within a
larger dataset will be needed to validate these observations
and permit adjustment for patient and procedure-related
covariates. Additionally, microembolization remains a sur-
rogate endpoint, and further studies are needed to deter-
mine whether reduction inMESs through procedural mod-
ifications impacts cognition, stroke, or other clinical
outcomes associated with carotid revascularization.
CONCLUSION
Flow reversal protection may represent a procedural
modification that reduces microembolization during ca-
rotid angioplasty and stenting. Carotid endarterectomy is
associated with significantly fewer microemboli than ca-
rotid angioplasty and stenting regardless of whether distal
filter protection or flow reversal is used. Further investiga-
tion is required to evaluate the relationship between proce-
dure-related microembolization and clinical outcomes.UTHOR CONTRIBUTIONS
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